Viatris

Price: 16.31

Company and Business Model

Viatris is a global healthcare company formed through the merger of Mylan and Upjohn, a division of Pfizer. It focuses on providing access to medicines, including generic and specialty pharmaceuticals. Major business segments include established brands, generics, and over-the-counter products. The company's primary revenue sources are from prescription medications and a diverse portfolio of therapeutic areas, including infectious diseases, oncology, and cardiovascular health.

Investment Profile

Viatris presents a neutral investment profile, appealing to both dividend and value investors due to its consistent dividend yield and established market presence. The stock's performance indicates moderate growth potential, while its current valuation suggests it may also attract value-focused investors. The investment horizon is more suitable for medium to long-term strategies, given the company's stability and market position.

Official website

Fundamental metrics (experimental)

EPS (TTM) — earnings per share for the last 12 months, $: -0.26 Risk
Revenue QoQ — quarter-over-quarter revenue growth: -5.0% ↓
EPS surprise: 7.1% better than expected
20d volatility: 1.8% stable
Dividend yield: 3.4% moderate last ex-date: 2026-03-09

FMP / FinFeed data updated: 2026-06-11

Forecast impact

neutral

Target Raised · Barclays · valid until 2026-06-18 · updated 2026-06-11

Target +39.5% target fill 71.7%

Reaction D5 -3.75% · D10 -4.56%

Impact Potential 0 · Risk 0 up to 30 days or until target is reached

Reco: Sell Potential: 43 Risk: 67 Updated: 2026-06-11 05:28

How recommendation works

Why AI thinks so:

Weak fundamentals and negative momentum raise concerns.

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

AI recommendation changes

Date	Before	After	Reason
2026-06-11 05:28	Hold	Sell	Weak fundamentals and negative momentum raise concerns.
2026-05-26 03:37	Sell	Hold	Weak fundamentals offset by stable dividend yield.
2026-05-18 04:34	Hold	Sell	Weak fundamentals and negative momentum raise concerns.
2026-05-08 15:20	—	Hold	Positive momentum, but fundamentals show weakness.
2026-05-08 06:39	Hold	Hold	Компания показывает положительную динамику роста за последние месяцы, однако отрицательный EPS и снижение выручки могут указывать на потенциальные риски.
2026-02-08 08:44	Buy	Hold	Компания Viatris демонстрирует значительный рост за последние два месяца, что указывает на положительные перспективы. Однако, отсутствие данных по EPS и дивидендам создает определенные риски.
2026-01-30 14:21	Hold	Buy	Компания Viatris демонстрирует значительный рост за последние 60 и 120 дней, что указывает на позитивные перспективы. Однако, высокая волатильность и отсутствие данных по EPS и доходам могут представлять определенные рис
2026-01-29 08:35	Buy	Hold	Компания Viatris демонстрирует положительную динамику на длительном горизонте, однако краткосрочные показатели показывают некоторую волатильность, что требует осторожности.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-05-19 09:18	Barclays	Target Raised	17 → 22	16.5
2026-05-08 13:28	Truist Financial	Target Raised	18 → 20	16.945
2026-02-09 10:05	UBS	Rating Upgraded	— → 18	14.58
2026-01-28 11:49	Piper Sandler	Target Raised	9 → 12	13.12
2026-01-16 12:14	Argus Research	Update	— → 15	12.84
2026-01-07 12:22	Truist Financial	Target Raised	15 → 16	12.4
2025-10-15 10:07	Truist Financial	Update	— → 15	9.93

Viatris (VTRS) Sees Revenue Growth and Pipeline Development Boosting Valuation Potential

06/04/2026, 11:31 AM investing growth healthcare Viatris

Viatris is experiencing a turnaround with improving sales and margins, driven by a strategic focus on drug development that could enhance its valuation and shareholder value. The company is poised for growth with a promising pipeline and cost-cutting measures that are already yielding positive results.